Shanthi Sivendran, MD, MSCR
Clinical Associate Professor of Medicine (Hematology-Oncology)
Department: Medicine
Contact information
Ann B. Barshinger Cancer Institute
2102 Harrisburg Pike
Lancaster, PA 17601
2102 Harrisburg Pike
Lancaster, PA 17601
Education:
BS (Science and Biology )
Pennsylvania State University, Schreyers Honors College , 1999.
MD (Medicine)
University of College Dublin School of Medicine , 2004.
MSCR (Science and Clinical Research )
Mount Sinai School of Medicine (NIH K30), 2011.
MS (Business Administration )
Isenberg School of Management , 2021.
Permanent linkBS (Science and Biology )
Pennsylvania State University, Schreyers Honors College , 1999.
MD (Medicine)
University of College Dublin School of Medicine , 2004.
MSCR (Science and Clinical Research )
Mount Sinai School of Medicine (NIH K30), 2011.
MS (Business Administration )
Isenberg School of Management , 2021.
Selected Publications
Sivendran S, Lynch S, McNaughton C, Wong R, Svetec S, Moore JH, Holliday R, Oyer RA, Newport K.: Anticancer Therapy at the End of Life: Lessons From a Community Cancer Institute. J Palliat Care. 36(2): 87-92, Apr 2021 Notes: doi: 10.1177/0825859719851484.Newport K, Sivendran S. : Including the Oncologist in Palliative Oncology: A Response to Nature of Discussions about Systemic Therapy Discontinuation or Hospice among Patients, Families, and Palliative Care Clinicians during Care for Incurable Cancer: A Qualitative Study. J Palliat Med. 23(4): 451-452, Apr 2020.
McNaughton CH, Horst M, Gehron E, Sivendran S, Nguyen J, Holliday R, Newport K. : Patterns of Support Service, Emergency Department and Hospital Utilization in Patients with Advanced Cancer: A Descriptive Study. J Palliat Care. 35(1): 34-39, Jan 2020.
Finlay E, Newport K, Sivendran S, Kilpatrick L, Owens M, Buss MK : Models of Outpatient Palliative Care Clinics for Patients With Cancer. J Oncol Pract 15(4): 187-193, Apr 2019.
Sivendran S, Jenkins S, Svetec S, Horst M, Newport K,Yost KJ, Yang M.: Illness Understanding of Oncology Patients in a Community-Based Cancer Institute. J Oncol Prac. 13(9): e800-e808. Sep 2017.
Wyluda E, Newport K, Sauder M, Sivendran S.: Safety and efficacy of vandetanib in the treatment of medullary thyroid cancer. Journal of Signs and Symptoms 3(2), Aug 2016.
Sivendran S, Galsky MD.: Adverse event reporting in oncology clinical trials - lost in translation? Expert Opin Drug Saf 15(7): 893-6, Jul 2016.
Sivendran S, Holliday R, Guittar R, Cox C, Newport K: The impact of a nurse practitioner-led symptom clinic on emergency department use in cancer patients. Journal of Community and Supportive Oncology 14(6): 268-272, 2016.
Perkins SH, Stensland KD, Galsky MD, Sivendran S.: Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies. Trials 16: 341, Aug 2015.
Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD.: Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol. 9(3): 195-204, Sep 2014.